Viral safety of blood derivatives by immune neutralization

Vox Sanguinis

Volumn 74, Issue SUPPL. 1, 1998, Pages 213-217

  Rollag, Halvor ^a,b   Solheim, B G ^a   Svennevig, J L ^a  

^a UNIVERSITY OF OSLO   (Norway)

^b OSLO UNIVERSITY HOSPITAL   (Norway)

Author keywords

Blood derivatives; Immune neutralization; Viruses

Indexed keywords

BLOOD CLOTTING FACTOR CONCENTRATE; BLOOD DERIVATIVE; NEUTRALIZING ANTIBODY; VIRUS ENVELOPE PROTEIN;

BLOOD TRANSFUSION; CONFERENCE PAPER; CYTOMEGALOVIRUS; DONOR; HEMOPHILIA; HEPATITIS A; HEPATITIS A VIRUS; HEPATITIS B VIRUS; HEPATITIS C VIRUS; HUMAN IMMUNODEFICIENCY VIRUS; PARVOVIRUS; PRIORITY JOURNAL; RECEPTOR BINDING; SAFETY; VIRUS INACTIVATION; VIRUS INFECTION; VIRUS TRANSMISSION;

EID: 0031824620     PISSN: 00429007     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1423-0410.1998.tb05475.x     Document Type: Conference Paper

References (43)

1. Vermylen J, Peerlinck K: Review of the hepatitis epidemics in hemophiliacs in Europe. Vox Sang 1994;67 Suppl 4:8-11.
2. Yap P: The viral safety of intravenous immune globulin. Clin Exp Immunol 1996;104 Suppl 1: 35-42.
3. Dimmock NJ: Update on the neutralization of animal viruses. Rev Med Virol 1995;5:165-179.
4. Spiller OB, Hanna SM, Devine DV, Tufaro F: Neutralization of cytomegalovrus virions: The role of complement. J Infect Dis 1997;176:339- 347.
5. Montefiori DC, Collman RG, Fouts TR, Zhou JY, Bilska M, Hoxie JA, Moore JP, Bolognesi DP: Evidence that antibody mediated neutralization of human immunodefiency virus type 1 by sera from infected individuals is independent of coreceptor usage. J Virol. 1998;72:1886-1893.
6. Wharton S, Calder LJ, Ruigrok RW, Skehel JJ, Steihauer DA, Wiley DC: Electron microscopy of antibody complexes of influenza virus haemagglutinin in the fused pH confirmation. EMBO J 1995;14:240-246.
7. R, Mosser A, Boeye A:Postadsorption neutralization of poliovirus. J Virol 1993;67:3126-3133.
8. Krause RM, Dimmock NJ, Morens DM:Summary of antibody workshop: The role of humoral immunity in the treatment and prevention of emerging and extant infectious diseases. J Infect Dis 1997;176:549-559.
9. Morens DM: Antibody dependent enhancement of infection and the pathogenesis of viral disease. Clin Infect Dis 1994;19:500-512.
10. Hamman J, Zou J, Horowitz B: Removal and inactivation of hepatitis A virus during processing of factor VIII concentrates. Vox Sang 1994; 67 Suppl I:72-76.
11. Li AM, Chang WK:Hepatitis A and B infections in transfusion-dependent thalassemia from endemic areas. J Paediatr Child Health 1991;27:228- 231.
12. Mauser-Bunschoten EP, Zaaijer HL, van Drimmelen AA, van den Berg HM, Roosendaal G, Lelie PN: Risk of hepatitis A in Dutch hemophilia patients. Thromb haemost 1995;74:616-618.
13. Evensen SA, Rollag H: Lack of evidence of sero- conversion to hepatitis A virus after more than 3 years treatment with solvent detergent treated clotting factors in Norwegian hemophiliacs. Lancet 1993;341:971-972.
14. Stapelton JT, Raina V. Winokur PL, Walters K, Klinzman D, Rosen E, McLinden JH: Antigenic and immunogenic properties of recombinant hepatitis A virus 14S and 70S subviral particles. J Virol 1993;1080-1085.
15. Brummelhuis HG, Over J, Duivis-Vorst CC, Wilson-de Sturler IA, Ates G, Hock PJ, Reerink- Brongers EE: Contributions to the optimal use of human blood IX. Elimination of hepatitis B transmission from infectious plasma derivatives. Vox Sang 1983;45:205-216
16. Tabor E, Aronson DL, Gerety RJ: Removal of hepatitis B virus infectivity from factor-IX complex by hepatitis B immune-globulin. Lancet 1980;ii: 68-70.
17. Ngui SL, O'Conell S, Eglin RP, Heptonstall J, Teo CG: Low detection rate andmaternal provenance of hepatitis B virus S gene mutants in cases of failed postnatal immunoprophylaxis in England and Wales. J Infect Dis 1997;176:1360- 1365.
18. McMahon G, Ehrlich PH, Moustafa ZA, McCarthy LA, Dottavio D, Tolpa MD, Nadler PI, Ostberg L: Genetic alterations in the gene encoding the major HbsAg: DNA and immunological analysis of recurrent HbsAg derived from monoclonal antibody-treated liver transplant patients. Hepatology 1992;15:757-766.
19. Howard CR, Allison LM: Hepatitis B surface antigen variation and protective immunity. Intervirology 1995;38:35-40.
20. Jongerius JM, Wester M, Cuypers HTM, van Osterdorp WR, Lelie PN, van der Poel CL, van Leeuwen EF: New hepatitis B virus mutant form in a blood donor that is undetectable in several hepatitis B surface antigen screening assays, Transfusion 1998;38:56-59.
21. Rollag H, Evensen SA, Glomstein A, Frøsland SS: The prevalence of hepatitis C virus antibodies among Norwegians with coagulation factor defects. Eur J Clin Microbiol Inf Dis 1990; 9:612-614.
22. Klein HG, Dodd RY, Dzik WH, Luban ML, Ness PM, Pisciotto P, Schiff PD, Snyder EL: Current status of solvent detergent-treated frozen plasma. Transfusion 1998; 38:102-107.
23. Krawczynski K, Alter MJ, Tankersley DL, Beach M, Robertson BH, Lambert S, Kuo G, Spelbring JE, Meeks E, Sinha S, Carson DA: Effect of immune globulin on the prevention of experimental hepatitis C virus infection. J infect Dis 1996;173,822-828.
24. Zibert A, Dudziak P, Schreier E, Roggendorf M: Chracterization of antibody response to hepatitis C virus protein E2 and significance of hypervariable region 1 specific antibodies in viral neutralization. Arch Virol 1997;142:523-534.
25. Booth JC, Kumar U, Webster D, Monjardino J, Thomas HC: Comparison of the rate of sequence variation in the hypervariable region of E2/NSq region of hepatitis C virus in normal and hypogammaglobulinemic patients. Hepatology 1998;27:223-227.
26. Busch MP, Operskalski EA, Mosley JW, Lee T.- E, Henrard D, Herman S, Sachs DH, Harris M, Huang W, Stram DO: Factors influencing human immunodeficiency virus type I transmission by blood transfusion J Infect Dis 1996;174:26-33.
27. Pilgrim AK, Pantaleo G, Cohen OJ, Fink LM, Zhou JY, Zhou JT, Bolognesi DP, Fauci AS, Montefiori DC: Neutralizing antibody responses to human immunodefiency virus type I in primary infection and long term-nonprogressive infection. J. Infect Dis 1997;176:924-932.
28. Hioe CE, Xu S, Chigurupati P, Burda S, Williams C, Gorney MK, Zolla-Panzer S: Neutralization of HIV-1 primary isolates by polyclonal and monoclonal antibodies. Int Immunol 1992;9:1281- 1291.
29. D'Souza MP, Livnut D, Bradac JA, Bridges SH: Evaluation of monoclonal antibodies to human immunodeficiency virus type 1 primary isolate by neutralization assays: performance criteria for selecting candidate antibodies for clinical trials. J.Infect Dis 1997;175:1056-1062.
30. Sanagustino, E, Mannucci PM, Gringeri A, Azzi A, Morfini M, Musso R, Santoro R, Schiavoni M: Transmission of parvovirus B19 by coagulation factor concentrated exposed to 100 degrees C heat after lyophilization. Transfusion 1997;37:517-522.
31. Yee TT, Cohen B J, Pasi KJ, Lee CA:Transmission of symptomatic parvovirus B19 infection by clotting factor concentrate. Br J Haematol 1996;93:457-459.
32. Cohen BJ, Beard S, Knowles WA, Ellis JS, Joske D, Goldman JM, Hewitt P, Ward K: Chronic anemia due to parvovirus B19 infection in a bone marrow transplant patient after platelet transfusion. Transfusion 1997;37:947-952.
33. Rollag H, Patou G, Pattison JR, Evensen SA, Degré M, Froøland SS, Glomstein A.: Prevalence of antibodies against parvovirus B19 in Norwegians with congenital coagulation factor defects treated with plasma products from small donor pools. Scand J Inf Dis 1991;23:675-679.
34. Wolf AD, Campion GV, Chishick A, Wise S, Cohen BJ, Klouda PT, Caul O, Dieppe PA: Clinical manifestations of human parvovirus in adults. Arch Intern Med 1989;149:1153-1156.
35. Anderson MI, Higgins PC, Davis LR, William JS, Jones SE, Kidd IM, Pattison JR, Tyrell DAJ: Experimental parvovirus infection in humans. J Infect. Dis 1985;152:257-265.
36. Chipman PR, Agbandje-Mckenna M, Kajigaya S, Brown KE, Young NS, Baker TS, Rossmann MG: Cryo-electron microscopy studies of empty capsids of human parvovirus B19 completed with its cellular receptor. Proc Natl Acad Sci USA 1996;93.7502-7506.
37. de Graan-Hentzen YC, Gratama JW, Mudde GC, Verdonk IF, Houbiers JG, Brand A,Sebens FW, van Loon AM, The T, Willemze R: Prevention of primary cytomegalovirus infection in patients with hematologic malignancies by intensive white cell depletion of blood products. Transfusion 1989;29:757-760.
38. Rollag H, Evensen S, Frøland SS, & Glomstein A: Serological markers for hepatitis B virus and cytomegalovirus in Norwegians with coagulation factor defects. Blut. 1990;60:93-96.
39. Navarro D, Paz P Tugizov S, Topp K, La Vail J, Pereira L: Glycoprotein B of human cytomegalovirus promotes virion penetration into cells, transmission of infected cell to cell, and fusion of infected cells. Virology 1993;197:143-158.
40. Urban M, Klein M, Britt WJ, Hassfurther E, Mach M: Glycoprotein H of human cytomegalovirus is a major antigen for the neutralizing humoral immune response. J Gen Virol 1996;77:1537- 1547.
41. Gupta CK, Leszczynski J, Gupta RK, Siber GR: IgG subclass antibodies to human cytomegalovirus (CMV) in normal human plasma samples and immune globulin and their neutralizing activities. Biologicals 1996;24:117-124.
42. Bale JF Jr, Petheram SJ, Souza IE, Murph JR: Cytomegalovirus reinfection in young children. J Pediatr 1996;128:347-352.
43. Rollag H, Sagedal S, Holter E, Degré M, Ariansen S, Nordal KP: Diagnosis of cytomegalovirus infection in kidney transplant recipients by a quantitative RNA-DNA hybrid capture assay for cytomegalovirus DNA in leukocytes. Eur J Clin Microbiol Inf Dis 1998;17: 124-127.